IRIS

The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment.

Teoli, M., Zangrilli, A., Chimenti, M.s., Talamonti, M., Bavetta, M., Graceffa, D., et al. (2012). Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012, 823854-823854 [10.1155/2012/823854].

Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study

CHIMENTI, MARIA SOLE;Talamonti, M;PERRICONE, ROBERTO;CHIMENTI, SERGIO
2012-01-01

Abstract

The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment.
2012
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Con Impact Factor ISI
Severity of Illness Index; Bone Resorption; Arthritis, Psoriatic; Humans; Retrospective Studies; Aged; C-Reactive Protein; Adult; Blood Sedimentation; Anti-Inflammatory Agents, Non-Steroidal; Follow-Up Studies; Middle Aged; Antibodies, Monoclonal, Humanized; Synovial Membrane; Female; Male
Teoli, M., Zangrilli, A., Chimenti, M.s., Talamonti, M., Bavetta, M., Graceffa, D., et al. (2012). Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012, 823854-823854 [10.1155/2012/823854].
Teoli, M; Zangrilli, A; Chimenti, Ms; Talamonti, M; Bavetta, M; Graceffa, D; Perricone, R; Chimenti, S
Articolo su rivista
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/77627
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact